US FDA approves Pegintron for treatment-failed hepatitis C patients
This article was originally published in Scrip
Executive Summary
Schering-Plough's Pegintron (peginterferon alfa-2b) has become the first pegylated interferon to be approved by the US FDA in combination with ribavirin, for patients with hepatitis C who have previously had an unsuccessful response to interferon therapy, or who have experienced a relapse.